Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zymeworks ( (ZYME) ) just unveiled an update.
In its third-quarter 2025 update, Zymeworks reported significant progress in its clinical trials and financial performance. The company presented encouraging Phase 1 data for ZW191, an ADC targeting folate receptor-⍺, and dosed the first patient in a Phase 1 trial for ZW251 targeting hepatocellular carcinoma. Zymeworks achieved a $25 million milestone from Johnson & Johnson and earned $1 million in royalties from Jazz and BeOne Medicines. The company also completed $22.7 million in share repurchases, strengthening shareholder value. Financially, Zymeworks reported a revenue increase to $27.6 million, driven by milestone revenues, and reduced its net loss to $19.6 million. With cash resources projected to fund operations into the second half of 2027, Zymeworks continues to focus on its partnership-driven business model and next-generation therapies.
The most recent analyst rating on (ZYME) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ strong revenue growth and positive earnings call sentiment are offset by significant profitability and cash flow challenges. The technical indicators suggest a strong upward trend, but valuation metrics highlight financial instability. Continued focus on improving profitability and managing cash flow is essential for future growth.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company aims to address difficult-to-treat conditions such as cancer, inflammation, and autoimmune diseases. Zymeworks utilizes complementary therapeutic platforms and a fully integrated drug development engine to engineer differentiated antibody-based therapeutic candidates. Notably, Zymeworks developed zanidatamab, a HER2-targeted bispecific antibody, which has received various regulatory approvals for treating HER2-positive biliary tract cancer.
Average Trading Volume: 650,046
Technical Sentiment Signal: Buy
Current Market Cap: $1.38B
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.